首頁 > 市場調查報告書 > 製藥

感染疾病

市場調查報告書

商品編碼

1709510

傳明酸的全球市場 (～2035年):製劑類型·用途·通路·終端用戶·劑型·各地區

Global Tranexamic Acid Market Research Report By Formulation Type, By Application, By Distribution Channel, By End User, By Dosage Form and By Regional Forecast to 2035

出版日期: 2025年03月05日 | 出版商:

Market Research Future | 英文 160 Pages | 訂單完成後即時交付

價格

簡介目錄圖表

全球氨甲環酸市場規模預計將從 2024 年的 10.3747 億美元增至 2035 年的 18.6199 億美元，預測期內的複合年增長率為 5.38%。

全球氨甲環酸市場正在迅速擴張，主要受醫療、製藥和化妝品領域對有效止血劑的需求不斷增長的推動。氨甲環酸越來越多地被用於預防手術、創傷和月經失調引起的過度出血，並在醫院、診所、家庭保健和緊急護理環境中得到越來越廣泛的應用。此外，由於人們廣泛認識到氨甲環酸在皮膚病學和化妝品應用方面的益處，特別是在治療色素沉著方面，市場正在擴大。

此外，藥物製劑技術和輸送機制的技術創新提高了生物利用度和治療效果，大大改變了市場環境。氨甲環酸的創新配方，如脂質體和奈米顆粒配方，有助於提高治療效果，同時減少副作用。此外，與其他活性成分的聯合療法的開發擴大了氨甲環酸在醫療和美容應用中的適應症範圍，進一步推動了市場成長。

區域分析

在全球氨甲環酸市場中，北美是主導地區，這得益於其先進的醫療保健基礎設施、較高的手術量以及對出血控制的認識不斷提高。由於創傷相關損傷數量的增加、支持性監管政策以及外科治療的擴大，美國和加拿大在氨甲環酸應用方面一直處於領先地位。

歐洲是一個成熟且監管良好的地區，其特點是廣泛的臨床可及性、強有力的政府支持和成熟的製藥製造能力。歐洲藥品管理局 (EMA) 和國家監管機構已批准氨甲環酸用於多種醫療用途，確保其在醫療機構中的標準化使用。亞太地區正在經歷快速增長，推動力包括藥品生產規模擴大、創傷性損傷發生率高、對婦幼健康的日益關注以及外科手術數量的增加。

本報告提供全球傳明酸的市場調查，彙整市場定義和概要，市場成長的各種影響因素分析，市場規模的轉變·預測，各種區分·地區/各主要國家的明細，競爭環境，主要企業簡介等資訊。

Global Tranexamic Acid Market Research Report By Formulation Type (Oral Tablets, Injectable Solutions, Topical Applications), By Application (Post-Surgical Bleeding, Menorrhagia, Trauma Cases, Dental Procedures), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By End User (Hospitals, Clinics, Home Care Settings), By Dosage Form (Low Dosage, Standard Dosage, High Dosage) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) Forecast to 2035

Market Overview

The Global Tranexamic Acid Market is anticipated to experience substantial growth during the review period, with a compound annual growth rate (CAGR) of 5.38%. It is anticipated that the market will attain a value of USD 1,861.99 million by the conclusion of the forecast period (2025-2035), with an estimated value of USD 1,037.47 million in 2024.

The global tranexamic acid market is expanding at a rapid pace, primarily due to the increasing demand for hemostatic agents that are effective in medical, pharmaceutical, and cosmetic applications. Tranexamic acid is being used more frequently to prevent excessive bleeding during surgeries, trauma cases, and menstrual disorders, which is promoting its widespread adoption in hospitals, clinics, home care, and emergency care settings. Furthermore, the market is expanding due to the increasing recognition of the advantages of tranexamic acid in dermatology and cosmetics, particularly for the treatment of hyperpigmentation.

The market landscape is being transformed by technological advancements in drug formulations and delivery mechanisms, which have enabled enhanced bioavailability and therapeutic efficacy. Innovative formulations of tranexamic acid, including liposomal and nanoparticle-based formulations, are improving treatment outcomes while diminishing adverse effects. Furthermore, the market is experiencing growth as a result of the expansion of the scope of tranexamic acid in medical and aesthetic applications through the development of combination therapies that incorporate other active ingredients.

Market Segmentation Analysis

In 2024, the oral segment held a market share of 47.67% based on Formulation Type and is anticipated to grow at a compound annual growth rate (CAGR) of 5.83% during the forecast period. This is primarily motivated by its broad accessibility, affordability, and convenience. The substantial market share of oral tablets is a result of their widespread prescription for conditions such as excessive menstrual bleeding and surgical bleeding prevention.

In 2024, the hospitals & clinics segment held a market share of 45.25% based on End User and is anticipated to grow at a compound annual growth rate (CAGR) of 5.23% during the forecast period. The high volume of surgical procedures, trauma cases, and critical care treatments that necessitate tranexamic acid for haemorrhage management is the reason for this growth.

Analysis of the Region

In the global tranexamic acid (TXA) market, North America is the dominant region due to its advanced healthcare infrastructure, high volume of surgical procedures, and growing awareness of blood loss management. The United States and Canada have been at the forefront of TXA adoption as a result of the increasing number of trauma-related injuries, supportive regulatory policies, and the expansion of surgical interventions.

Europe is a mature and well-regulated TXA market, characterized by pervasive clinical adoption, strong government support, and well-established pharmaceutical manufacturing capabilities. TXA has been certified for a variety of medical applications by the European Medicines Agency (EMA) and national regulatory bodies, thereby guaranteeing standardized usage across healthcare institutions. The Asia-Pacific (APAC) region is experiencing rapid expansion in the tranexamic acid (TXA) market, which is being driven by expanding pharmaceutical production, high trauma incidences, rising maternal healthcare concerns, and increasing surgical volumes. Countries such as Germany are among those in this region. The adoption of TXA is being led by countries such as China, India, Japan, South Korea, and Australia, which are benefiting from an increasing number of clinical applications, growing awareness about blood loss management, and rising healthcare investments.

Major Players

Pfizer Inc., Fresenius Kabi AG, Teva Pharmaceuticals, Maxwellia Ltd, Aurobindo Pharma, Sun Pharma, Apotex Inc, Ferring Pharmaceuticals, Amring Pharmaceuticals Inc., and Exela Pharma Sciences are among the notable participants in the industry.

1 EXECUTIVE SUMMARY

1.1 OVERVIEW
1.2 MARKET ATTRACTIVENESS ANALYSIS
1.3 GLOBAL TRANEXAMIC ACID MARKET, BY FORMULATION TYPE
1.4 GLOBAL TRANEXAMIC ACID MARKET, BY APPLICATION
1.5 GLOBAL TRANEXAMIC ACID MARKET, BY END USER
1.6 GLOBAL TRANEXAMIC ACID MARKET, BY REGION

2 MARKET INTRODUCTION

2.1 DEFINITION
2.2 SCOPE OF THE STUDY
2.3 RESEARCH OBJECTIVE
2.4 MARKET STRUCTURE

3 RESEARCH METHODOLOGY

3.1 OVERVIEW
3.2 DATA FLOW
- 3.2.1 Data Mining Process
3.3 PURCHASED DATABASE:
3.4 SECONDARY SOURCES:
- 3.4.1 Secondary Research Data Flow:
3.5 PRIMARY RESEARCH:
- 3.5.1 Primary Research Data Flow:
- 3.5.2 Primary Research: Number of Interviews conducted
3.6 APPROACHES FOR MARKET SIZE ESTIMATION:
- 3.6.1 Revenue Analysis Approach
3.7 DATA FORECASTING
- 3.7.1 Data forecasting Type
3.8 DATA MODELING
- 3.8.1 Microeconomic Factor Analysis:
- 3.8.2 Data modeling:
3.9 TEAMS AND ANALYST CONTRIBUTION

4 MARKET DYNAMICS

4.1 INTRODUCTION
4.2 GROWTH PARAMETERS MAPPED - DRIVERS
- 4.2.1 Increasing Surgical Procedures
- 4.2.2 Growing Prevalence of Trauma Cases
- 4.2.3 Growing Prevalence of Heavy Menstrual Bleeding (HMB)
4.3 WHAT ARE THE CHALLENGES FACED BY INDUSTRY PARTICIPANTS?
- 4.3.1 Stringent Regulatory Requirements
- 4.3.2 High R&D Costs for New Formulations
4.4 MARKET OPPORTUNITIES MAPPED
- 4.4.1 Rising Demand for Minimally Invasive & Non-Surgical Treatment Options
- 4.4.2 Untapped Potential in Emerging Markets

5 MARKET FACTOR ANALYSIS

5.1 PORTER'S FIVE FORCES MODEL
- 5.1.1 Bargaining Power of Suppliers
- 5.1.2 Bargaining Power of Buyers
- 5.1.3 Threat of New Entrants
- 5.1.4 Threat of Substitutes
- 5.1.5 Intensity of Rivalry
5.2 COVID-19 IMPACT ANALYSIS
- 5.2.1 Impact on R & D
- 5.2.2 Impact on Supply Chain
- 5.2.3 Impact on Pricing

6 GLOBAL TRANEXAMIC ACID MARKET, BY FORMULATION TYPE

6.1 INTRODUCTION
6.2 ORAL
6.3 INJECTABLE
6.4 TROPICAL

7 GLOBAL TRANEXAMIC ACID MARKET, BY APPLICATION

7.1 INTRODUCTION
7.2 MENORRHAGIA
7.3 SURGICAL BLEEDING CONTROL
7.4 TRAUMA AND INJURY
7.5 HEREDITARY ANGIOEDEMA (HAE)
7.6 POSTPARTUM HEMORRHAGE
7.7 OTHERS

8 GLOBAL TRANEXAMIC ACID MARKET, BY END USER

8.1 INTRODUCTION
8.2 HOSPITALS & CLINICS
8.3 AMBULATORY SURGICAL CENTERS
8.4 OTHERS

9 GLOBAL TRANEXAMIC ACID MARKET, BY REGION

9.1 OVERVIEW
9.2 NORTH AMERICA
- 9.2.1 US
- 9.2.2 CANADA
9.3 EUROPE
- 9.3.1 GERMANY
- 9.3.2 UK
- 9.3.3 FRANCE
- 9.3.4 ITALY
- 9.3.5 SPAIN
- 9.3.6 REST OF EUROPE
9.4 ASIA-PACIFIC
- 9.4.1 CHINA
- 9.4.2 INDIA
- 9.4.3 JAPAN
- 9.4.4 SOUTH KOREA
- 9.4.5 AUSTRALIA
- 9.4.6 REST OF ASIA-PACIFIC
9.5 REST OF THE WORLD
- 9.5.1 MIDDLE EAST
- 9.5.2 AFRICA
- 9.5.3 LATIN AMERICA

10 COMPETITIVE LANDSCAPE

10.1 INTRODUCTION
10.2 MARKET SHARE ANALYSIS, 2024
10.3 COMPETITION DASHBOARD
- 10.3.1 PRODUCT PORTFOLIO
- 10.3.2 REGIONAL PRESENCE
- 10.3.3 STRATEGIC ALLIANCES
- 10.3.4 INDUSTRY EXPERIENCES
10.4 WHO ARE THE MAJOR DISRUPTORS & INNOVATORS
10.5 WHAT STRATEGIES ARE BEING ADOPTED BY MARKET LEADERS
10.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
- 10.6.1 Merger and Acquisition
- 10.6.2 Product launch

11 COMPANY PROFILES

11.1 PFIZER INC
- 11.1.1 COMPANY OVERVIEW
- 11.1.2 FINANCIAL OVERVIEW
- 11.1.3 PRODUCTS OFFERED
- 11.1.4 KEY DEVELOPMENTS
- 11.1.5 SWOT ANALYSIS
- 11.1.6 Key Strategy
11.2 FRESENIUS KABI USA, LLC
- 11.2.1 COMPANY OVERVIEW
- 11.2.2 FINANCIAL OVERVIEW
- 11.2.3 PRODUCTS OFFERED
- 11.2.4 KEY DEVELOPMENTS
- 11.2.5 SWOT ANALYSIS
- 11.2.6 Key Strategy
11.3 TEVA PHARMACEUTICAL INDUSTRIES LTD.
- 11.3.1 COMPANY OVERVIEW
- 11.3.2 FINANCIAL OVERVIEW
- 11.3.3 PRODUCTS OFFERED
- 11.3.4 KEY DEVELOPMENTS
- 11.3.5 SWOT ANALYSIS
- 11.3.6 Key Strategy
11.4 MAXWELLIA LTD.
- 11.4.1 COMPANY OVERVIEW
- 11.4.2 PRODUCTS OFFERED
- 11.4.3 KEY DEVELOPMENTS
- 11.4.4 SWOT ANALYSIS
- 11.4.5 Key Strategy
11.5 AUROBINDO PHARMA USA
- 11.5.1 COMPANY OVERVIEW
- 11.5.2 PRODUCTS OFFERED
- 11.5.3 KEY DEVELOPMENTS
- 11.5.4 SWOT ANALYSIS
- 11.5.5 Key Strategy
11.6 SUN PHARMACEUTICAL INDUSTRIES LTD.
- 11.6.1 COMPANY OVERVIEW
- 11.6.2 FINANCIAL OVERVIEW
- 11.6.3 PRODUCTS OFFERED
- 11.6.4 KEY DEVELOPMENTS
- 11.6.5 SWOT ANALYSIS
- 11.6.6 Key Strategy
11.7 APOTEX INC.
- 11.7.1 COMPANY OVERVIEW
- 11.7.2 PRODUCTS OFFERED
- 11.7.3 KEY DEVELOPMENTS
- 11.7.4 SWOT ANALYSIS
- 11.7.5 Key Strategy
11.8 FERRING PHARMACEUTICALS
- 11.8.1 COMPANY OVERVIEW
- 11.8.2 PRODUCTS OFFERED
- 11.8.3 KEY DEVELOPMENTS
- 11.8.4 SWOT ANALYSIS
- 11.8.5 Key Strategy
11.9 NORDIC PHARMA, INC
- 11.9.1 COMPANY OVERVIEW
- 11.9.2 PRODUCTS OFFERED
- 11.9.3 KEY DEVELOPMENTS
- 11.9.4 SWOT ANALYSIS
- 11.9.5 Key Strategy
11.10 EXELA PHARMA SCIENCES LLC
- 11.10.1 COMPANY OVERVIEW
- 11.10.2 PRODUCTS OFFERED
- 11.10.3 KEY DEVELOPMENTS
- 11.10.4 SWOT ANALYSIS
- 11.10.5 Key Strategy

12 DATA CITATIONS

簡介目錄圖表

LIST OF TABLES

TABLE 1 QFD MODELING FOR MARKET SHARE ASSESSMENT
TABLE 2 GLOBAL TRANEXAMIC ACID MARKET, BY FORMULATION TYPE, 2019-2035 (USD MILLION)
TABLE 3 GLOBAL TRANEXAMIC ACID MARKET, FOR ORAL, BY REGION, 2019-2035 (USD MILLION)
TABLE 4 GLOBAL TRANEXAMIC ACID MARKET, FOR INJECTABLE, BY REGION, 2019-2035 (USD MILLION)
TABLE 5 GLOBAL TRANEXAMIC ACID MARKET, FOR TROPICAL, BY REGION, 2019-2035 (USD MILLION)
TABLE 6 GLOBAL TRANEXAMIC ACID MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
TABLE 7 GLOBAL TRANEXAMIC ACID MARKET, FOR MENORRHAGIA, BY REGION, 2019-2035 (USD MILLION)
TABLE 8 GLOBAL TRANEXAMIC ACID MARKET, FOR SURGICAL BLEEDING CONTROL, BY REGION, 2019-2035 (USD MILLION)
TABLE 9 GLOBAL TRANEXAMIC ACID MARKET, FOR TRAUMA AND INJURY, BY REGION, 2019-2035 (USD MILLION)
TABLE 10 GLOBAL TRANEXAMIC ACID MARKET, FOR HEREDITARY ANGIOEDEMA (HAE), BY REGION, 2019-2035 (USD MILLION)
TABLE 11 GLOBAL TRANEXAMIC ACID MARKET, FOR POSTPARTUM HEMORRHAGE, BY REGION, 2019-2035 (USD MILLION)
TABLE 12 GLOBAL TRANEXAMIC ACID MARKET, FOR OTHERS, BY REGION, 2019-2035 (USD MILLION)
TABLE 13 GLOBAL TRANEXAMIC ACID MARKET, BY END USER, 2019-2035 (USD MILLION)
TABLE 14 GLOBAL TRANEXAMIC ACID MARKET, FOR HOSPITALS & CLINICS, BY REGION, 2019-2035 (USD MILLION)
TABLE 15 GLOBAL TRANEXAMIC ACID MARKET, FOR AMBULATORY SURGICAL CENTERS, BY REGION, 2019-2035 (USD MILLION)
TABLE 16 GLOBAL TRANEXAMIC ACID MARKET, FOR OTHERS, BY REGION, 2019-2035 (USD MILLION)
TABLE 17 GLOBAL TRANEXAMIC ACID MARKET, BY REGION, 2019-2035 (USD MILLION)
TABLE 18 NORTH AMERICA TRANEXAMIC ACIDS MARKET, BY COUNTRY, 2019-2035 (USD MILLION)
TABLE 19 NORTH AMERICA: TRANEXAMIC ACID MARKET, BY FORMULATION TYPE, 2019-2035 (USD MILLION)
TABLE 20 NORTH AMERICA: TRANEXAMIC ACID MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
TABLE 21 NORTH AMERICA: TRANEXAMIC ACID MARKET, BY END USER, 2019-2035 (USD MILLION)
TABLE 22 US: TRANEXAMIC ACID MARKET, BY FORMULATION TYPE, 2019-2035 (USD MILLION)
TABLE 23 US: TRANEXAMIC ACID MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
TABLE 24 US: TRANEXAMIC ACID MARKET, BY END USER, 2019-2035 (USD MILLION)
TABLE 25 CANADA: TRANEXAMIC ACID MARKET, BY FORMULATION TYPE, 2019-2035 (USD MILLION)
TABLE 26 CANADA: TRANEXAMIC ACID MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
TABLE 27 CANADA: TRANEXAMIC ACID MARKET, BY END USER, 2019-2035 (USD MILLION)
TABLE 28 EUROPE: TRANEXAMIC ACIDS MARKET, BY COUNTRY, 2019-2035 (USD MILLION)
TABLE 29 EUROPE: TRANEXAMIC ACID MARKET, BY FORMULATION TYPE, 2019-2035 (USD MILLION)
TABLE 30 EUROPE: TRANEXAMIC ACID MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
TABLE 31 EUROPE: TRANEXAMIC ACID MARKET, BY END USER, 2019-2035 (USD MILLION)
TABLE 32 GERMANY: TRANEXAMIC ACID MARKET, BY FORMULATION TYPE, 2019-2035 (USD MILLION)
TABLE 33 GERMANY: TRANEXAMIC ACID MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
TABLE 34 GERMANY: TRANEXAMIC ACID MARKET, BY END USER, 2019-2035 (USD MILLION)
TABLE 35 UK: TRANEXAMIC ACID MARKET, BY FORMULATION TYPE, 2019-2035 (USD MILLION)
TABLE 36 UK: TRANEXAMIC ACID MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
TABLE 37 UK: TRANEXAMIC ACID MARKET, BY END USER, 2019-2035 (USD MILLION)
TABLE 38 FRANCE: TRANEXAMIC ACID MARKET, BY FORMULATION TYPE, 2019-2035 (USD MILLION)
TABLE 39 FRANCE: TRANEXAMIC ACID MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
TABLE 40 FRANCE: TRANEXAMIC ACID MARKET, BY END USER, 2019-2035 (USD MILLION)
TABLE 41 ITALY: TRANEXAMIC ACID MARKET, BY FORMULATION TYPE, 2019-2035 (USD MILLION)
TABLE 42 ITALY: TRANEXAMIC ACID MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
TABLE 43 ITALY: TRANEXAMIC ACID MARKET, BY END USER, 2019-2035 (USD MILLION)
TABLE 44 SPAIN: TRANEXAMIC ACID MARKET, BY FORMULATION TYPE, 2019-2035 (USD MILLION)
TABLE 45 SPAIN: TRANEXAMIC ACID MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
TABLE 46 SPAIN: TRANEXAMIC ACID MARKET, BY END USER, 2019-2035 (USD MILLION)
TABLE 47 REST OF EUROPE: TRANEXAMIC ACID MARKET, BY FORMULATION TYPE, 2019-2035 (USD MILLION)
TABLE 48 REST OF EUROPE: TRANEXAMIC ACID MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
TABLE 49 REST OF EUROPE: TRANEXAMIC ACID MARKET, BY END USER, 2019-2035 (USD MILLION)
TABLE 50 ASIA-PACIFIC: TRANEXAMIC ACID MARKET, BY COUNTRY, 2019-2035 (USD MILLION)
TABLE 51 ASIA-PACIFIC: TRANEXAMIC ACID MARKET, BY FORMULATION TYPE, 2019-2035 (USD MILLION)
TABLE 52 ASIA-PACIFIC: TRANEXAMIC ACID MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
TABLE 53 ASIA-PACIFIC: TRANEXAMIC ACID MARKET, BY END USER, 2019-2035 (USD MILLION)
TABLE 54 CHINA: TRANEXAMIC ACID MARKET, BY FORMULATION TYPE, 2019-2035 (USD MILLION)
TABLE 55 CHINA: TRANEXAMIC ACID MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
TABLE 56 CHINA: TRANEXAMIC ACID MARKET, BY END USER, 2019-2035 (USD MILLION)
TABLE 57 INDIA: TRANEXAMIC ACID MARKET, BY FORMULATION TYPE, 2019-2035 (USD MILLION)
TABLE 58 INDIA: TRANEXAMIC ACID MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
TABLE 59 INDIA: TRANEXAMIC ACID MARKET, BY END USER, 2019-2035 (USD MILLION)
TABLE 60 JAPAN: TRANEXAMIC ACID MARKET, BY FORMULATION TYPE, 2019-2035 (USD MILLION)
TABLE 61 JAPAN: TRANEXAMIC ACID MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
TABLE 62 JAPAN: TRANEXAMIC ACID MARKET, BY END USER, 2019-2035 (USD MILLION)
TABLE 63 SOUTH KOREA: TRANEXAMIC ACID MARKET, BY FORMULATION TYPE, 2019-2035 (USD MILLION)
TABLE 64 SOUTH KOREA: TRANEXAMIC ACID MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
TABLE 65 SOUTH KOREA: TRANEXAMIC ACID MARKET, BY END USER, 2019-2035 (USD MILLION)
TABLE 66 AUSTRALIA: TRANEXAMIC ACID MARKET, BY FORMULATION TYPE, 2019-2035 (USD MILLION)
TABLE 67 AUSTRALIA: TRANEXAMIC ACID MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
TABLE 68 AUSTRALIA: TRANEXAMIC ACID MARKET, BY END USER, 2019-2035 (USD MILLION)
TABLE 69 REST OF ASIA-PACIFIC: TRANEXAMIC ACID MARKET, BY FORMULATION TYPE, 2019-2035 (USD MILLION)
TABLE 70 REST OF ASIA-PACIFIC: TRANEXAMIC ACID MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
TABLE 71 REST OF ASIA-PACIFIC: TRANEXAMIC ACID MARKET, BY END USER, 2019-2035 (USD MILLION)
TABLE 72 REST OF THE WORLD: TRANEXAMIC ACID MARKET, BY COUNTRY, 2019-2035 (USD MILLION)
TABLE 73 REST OF THE WORLD: TRANEXAMIC ACID MARKET, BY FORMULATION TYPE, 2019-2035 (USD MILLION)
TABLE 74 REST OF THE WORLD: TRANEXAMIC ACID MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
TABLE 75 REST OF THE WORLD: TRANEXAMIC ACID MARKET, BY END USER, 2019-2035 (USD MILLION)
TABLE 76 MIDDLE EAST: TRANEXAMIC ACID MARKET, BY FORMULATION TYPE, 2019-2035 (USD MILLION)
TABLE 77 MIDDLE EAST: TRANEXAMIC ACID MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
TABLE 78 MIDDLE EAST: TRANEXAMIC ACID MARKET, BY END USER, 2019-2035 (USD MILLION)
TABLE 79 AFRICA: TRANEXAMIC ACID MARKET, BY FORMULATION TYPE, 2019-2035 (USD MILLION)
TABLE 80 AFRICA: TRANEXAMIC ACID MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
TABLE 81 AFRICA: TRANEXAMIC ACID MARKET, BY END USER, 2019-2035 (USD MILLION)
TABLE 82 LATIN AMERICA: TRANEXAMIC ACID MARKET, BY FORMULATION TYPE, 2019-2035 (USD MILLION)
TABLE 83 LATIN AMERICA: TRANEXAMIC ACID MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
TABLE 84 LATIN AMERICA: TRANEXAMIC ACID MARKET, BY END USER, 2019-2035 (USD MILLION)
TABLE 85 MERGER AND ACQUISITION
TABLE 86 PRODUCT LAUNCH
TABLE 87 PFIZER INC: PRODUCTS OFFERED
TABLE 88 FRESENIUS KABI USA, LLC: PRODUCTS OFFERED
TABLE 89 TEVA PHARMACEUTICAL INDUSTRIES LTD: PRODUCTS OFFERED
TABLE 90 MAXWELLIA LTD.: PRODUCTS OFFERED
TABLE 91 AUROBINDO PHARMA USA: PRODUCTS OFFERED
TABLE 92 SUN PHARMACEUTICAL INDUSTRIES LTD.: PRODUCTS OFFERED
TABLE 93 APOTEX INC.: PRODUCTS OFFERED
TABLE 94 FERRING PHARMACEUTICALS: PRODUCTS OFFERED
TABLE 95 NORDIC PHARMA, INC: PRODUCTS OFFERED
TABLE 96 EXELA PHARMA SCIENCES LLC: PRODUCTS OFFERED

LIST OF FIGURES

FIGURE 1 MARKET ATTRACTIVENESS ANALYSIS: GLOBAL TRANEXAMIC ACID MARKET, 2024
FIGURE 2 GLOBAL TRANEXAMIC ACID MARKET ANALYSIS, BY FORMULATION TYPE, 2024
FIGURE 3 GLOBAL TRANEXAMIC ACID ANALYSIS, BY APPLICATION, 2024
FIGURE 4 GLOBAL TRANEXAMIC ACID ANALYSIS, BY END USER, 2024
FIGURE 5 GLOBAL TRANEXAMIC ACID MARKET ANALYSIS, BY REGION, 2024
FIGURE 1 GLOBAL TRANEXAMIC ACID MARKET: STRUCTURE
FIGURE 2 GLOBAL TRANEXAMIC ACID MARKET: MARKET GROWTH FACTOR ANALYSIS (2019-2035)
FIGURE 3 DRIVER IMPACT ANALYSIS (2019-2035)
FIGURE 4 PORTER'S FIVE FORCES MODEL: GLOBAL TRANEXAMIC ACID MARKET
FIGURE 5 GLOBAL TRANEXAMIC ACID MARKET, BY FORMULATION TYPE, SEGMENT ATTRACTIVENESS ANALYSIS
FIGURE 6 GLOBAL TRANEXAMIC ACID MARKET, BY FORMULATION TYPE, 2024 & 2035 (USD MILLION)
FIGURE 7 GLOBAL TRANEXAMIC ACID MARKET SHARE (%), BY FORMULATION TYPE, 2024
FIGURE 8 GLOBAL TRANEXAMIC ACID MARKET, BY APPLICATION, SEGMENT ATTRACTIVENESS ANALYSIS
FIGURE 9 GLOBAL TRANEXAMIC ACID MARKET, BY APPLICATION, 2024 & 2035 (USD MILLION)
FIGURE 10 GLOBAL TRANEXAMIC ACID MARKET SHARE (%), BY APPLICATION, 2024
FIGURE 11 GLOBAL TRANEXAMIC ACID MARKET, BY END USER, SEGMENT ATTRACTIVENESS ANALYSIS
FIGURE 12 GLOBAL TRANEXAMIC ACID MARKET, BY END USER, 2024 & 2035 (USD MILLION)
FIGURE 13 GLOBAL TRANEXAMIC ACID MARKET SHARE (%), BY END USER, 2024
FIGURE 14 GLOBAL TRANEXAMIC ACID MARKET, BY REGION, 2024 & 2035 (USD MILLION)
FIGURE 15 GLOBAL TRANEXAMIC ACID MARKET SHARE (%), BY REGION, 2024
FIGURE 16 NORTH AMERICA: TRANEXAMIC ACID MARKET, BY COUNTRY, 2024 & 2035 (USD MILLION)
FIGURE 17 NORTH AMERICA: TRANEXAMIC ACID MARKET SHARE (%), BY COUNTRY, 2024
FIGURE 18 EUROPE: TRANEXAMIC ACIDS MARKET SHARE, BY COUNTRY, 2024 & 2035 (USD MILLION)
FIGURE 19 EUROPE: TRANEXAMIC ACIDS MARKET SHARE, BY COUNTRY, 2024 (%)
FIGURE 20 ASIA-PACIFIC: TRANEXAMIC ACID MARKET SHARE, BY COUNTRY, 2024 & 2035 (USD MILLION)
FIGURE 21 ASIA-PACIFIC: TRANEXAMIC ACID MARKET SHARE, BY COUNTRY, 2024 (%)
FIGURE 22 REST OF THE WORLD: TRANEXAMIC ACID MARKET SHARE, BY COUNTRY, 2024 & 2035 (USD MILLION)
FIGURE 23 REST OF THE WORLD: TRANEXAMIC ACID MARKET SHARE, BY REGION, 2024 (%)
FIGURE 24 GLOBAL TRANEXAMIC ACID MARKET PLAYERS: COMPETITIVE ANALYSIS, 2024
FIGURE 25 COMPETITOR DASHBOARD: GLOBAL TRANEXAMIC ACID MARKET
FIGURE 26 PFIZER INC: SWOT ANALYSIS
FIGURE 27 FRESENIUS KABI USA, LLC: SWOT ANALYSIS
FIGURE 28 TEVA PHARMACEUTICAL INDUSTRIES LTD: SWOT ANALYSIS
FIGURE 29 MAXWELLIA LTD: SWOT ANALYSIS
FIGURE 30 AUROBINDO PHARMA USA: SWOT ANALYSIS
FIGURE 31 SUN PHARMACEUTICAL INDUSTRIES LTD.: SWOT ANALYSIS
FIGURE 32 APOTEX INC.: SWOT ANALYSIS
FIGURE 33 FERRING PHARMACEUTICALS: SWOT ANALYSIS
FIGURE 34 NORDIC PHARMA, INC: SWOT ANALYSIS
FIGURE 35 EXELA PHARMA SCIENCES LLC: SWOT ANALYSIS